A phase III study of Calmangafodipir (PledOx®) in patients treated adjuvantly for colorectal cancer
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Calmangafodipir (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- 03 Nov 2016 New trial record
- 20 Oct 2016 According to a PledPharma media release, top-line results from the study are anticipated in the year 2020.
- 20 Oct 2016 According to a PledPharma media release, this trial will form the basis for a new drug application (NDA) to the Food and Drug Administration (FDA) in the US and for a marketing authorization application (MAA) to the European Medicines Agency (EMA) in Europe.